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educate and prepare head and neck cancer patients for 
upcoming surgery where manibulectomy is part of the surgical 
procedure. This has been used to educate three consecutive 
patients.  
Methods and Materials: For each patient, detailed anatomy of 
the mandible was obtained via CT images which were already 
required for patient staging and treatment. Images were 
segmented (3D Doctor, Able Software) and the resulting model 
was exported as an STL file to software controlling the printer 
(Repetier-Host), converted to gcode (Slic3r) and printed on a 
consumer-Grade 3D printer (MakerGear, M2). To improve quality, 
a slow print speed of about 30 mm/second was used. A layer 
thickness of 0.3 mm resulted in reasonable print times. 
Results: We were able to create a precise and detailed life-size 
model of the patient’s mandible for three patients. Each model 
included minute normal anatomy as well as the defect created 
by the tumour.  
The surgeon involved was able to use the models during clinical 
visits to educate the patients. He was able to better illustrate 
his plan to perform a mandibulectomy to fully remove the 
tumour and surrounding healthy bone. He was also able to show 
the supportive, metal reconstruction plate which would be 
moulded to fit the mandible. In these cases, each patient was 
able to give suggestions based on personal preferences and their 
new understanding of the anatomy displayed on the model. This 
resulted in a decrease in patient anxiety. It also led to a modest 
change in surgical planning and management. The models were 
subsequently used to customize the reconstructive plates. 
Conclusions: The use of 3D printing technology to create precise 
anatomic models in order to educate patients is a novel and 
promising approach. When patients are able to visualize their 
own anatomy and the anatomy of an invading tumour, it allows 
them to be more involved in their own care. There is a decrease 
in anxiety and in some instances, it can even lead to technical 
changes in management. Although 3D printing has already been 
used to save valuable operating room time and in the medical 
education of other health care professionals, we found that it 
can be effectively used as a valuable, patient education tool. 
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Purpose: Radioactive iodine (RAI) dose for early differentiated 
thyroid cancer (DTC) has decreased from 100mCi to 30mCi. There 
is little long-term data to determine the effect, if any, on disease 
recurrence. Our analysis aims to identify clinicopathologic 
factors associated with disease recurrence in DTC. 
Methods and Materials: Patients diagnosed between 1996 and 
2008 with Stage I-II DTC (papillary and follicular) who had 
undergone surgical resection followed by RAI and had been 
followed for five years with ultrasound, thyroglobulin, and whole 
body thyroid scans were eligible for analysis. We identified 219 
eligible patients from the database. Patients were stratified into 
two groups by initial RAI dose (≤ 50 versus > 50 mCi). Recurrence 
was defined as an elevated stimulated thyroglobulin 
(biochemical recurrence) or biopsy-proven disease. Test for 
significant differences between the survival and relapse curves 
was done using the log-rank test. Survival and relapse curves 
were calculated using the Kaplan-Meier method. 
Results: A greater proportion of patients in the high dose RAI 
group had extrathyroidal extension (ETE) (52.0% versus 24.8%, p 
= 0.001). Groups did not differ otherwise in baseline 
characteristics. Patients who recurred more frequently had ETE 
(43.7% versus 21.9%, p = 0.003) and lymph node (LN) metastases 
(74.7% versus 38.3%, p < 0.001) at diagnosis. Tumour size, 
multifocality, vascular invasion, patient age and gender did not 
predict for recurrence. On multivariate analysis, LN metastases 
at diagnosis predicted for local and distant recurrence (HR 2.67, 
1.17-6.05). Female gender (HR 4.08, 1.04-16.05) and initial dose 
≤ 50 mCi (HR 6.30, 1.30-30.55) predicted for local recurrence. 
Median time to recurrence was shorter in patients receiving an 
initial dose ≤ 50 mCi (23.2 versus 47.6 months, p < 0.001). Median 
survival time did not differ between dose groups (105.8 versus 
114.1 months, p 0.773). On multivariate analysis, patients 
treated with initial dose ≤ 50 mCi who had ETE and LN metastases 
at diagnosis were more likely to recur (p = 0.004). Patients with 
both risk factors had a median time to recurrence of 25.2 months 
(≤ 50 mCi) versus 120.9 months (> 50 mCi), p = 0.04.  
Conclusions: Patients treated with ≤ 50 mCi had a significantly 
shorter mean time to disease recurrence. In patients treated 
with ≤ 50 mCi, ETE and lymph node metastases at diagnosis 
predicted for recurrence. Patients presenting with these risk 
factors may require an initial RAI dose > 50 mCi. Further analyses 
are required to confirm these findings.  
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Purpose: The radiotherapy volumes in anaplastic (ATC) and 
differentiated thyroid carcinomas (DTC) are controversial, 
particularly with respect to the necessity of prophylactic nodal 
treatment. 
Methods and Materials: We retrospectively examined the 
patterns of failure following post-operative intensity modulated 
radiation therapy in 30 DTC and five ATC patients treated 
radically from 2006-2012. Radiotherapy volumes routinely 
included the thyroidectomy bed, level III-VI, with level II and V 
partially included, for both ATC and DTC. Patients who received 
primary radiotherapy, patients treated for recurrent disease, 
and patients who received palliative radiotherapy were excluded 
(n = 245). No patient received concurrent chemotherapy. CT 
scans were rigidly registered with the original radiotherapy plans 
and dose to the recurrence volume was determined. Recurrences 
were in-field if > 95% received 95% of the prescribed dose, out-
of-field if < 20% received 95% of the dose, and marginal 
otherwise. Overall survival rate was calculated using the Kaplan-
Meier method. The cumulative incidence rates of locoregional 
recurrence and distant recurrence were calculated with death as 
the competing risk. 
Results: Median radiotherapy dose was 52Gy in 20 fractions for 
ATC (range: 40 Gy/16 – 60 Gy/40 BID) and 66 Gy in 33 fractions 
for DTC (range: 60 Gy/30 – 66 Gy/33). Positive margins and 
extracapsular extension were present in all ATC patients, and in 
80% and 93% of DTC patients, respectively. 4/30 DTC patients 
developed regional recurrence: one in-field (level II/III) and 
three out-of-field (all in level II). Two patients underwent 
salvage neck dissections. Six patients developed metastatic 
disease. There were no local recurrences. Five-year overall 
survival, locoregional recurrence, and distant recurrence were 
93%, 17%, and 23%, respectively. Among ATC cases, five out of 
five recurred at seven sites: two were local, and five regional: 
one marginal (intramuscular to the digastric) and four out-of-
field (one retropharyngeal, one in soft tissues near the 
manubrium, and two lateral to the sternocleidomastoid). All ATC 
patients developed lung metastases with a median survival of 1.2 
years. 
Conclusions: In DTC, locoregional recurrence is unusual 
following radiotherapy. Out-of-field DTC recurrences occurred in 
level II, however, increasing treatment volumes to level II must 
be balanced against an expected greater risk of toxicity. 
